Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) reached a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as ...

Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced positive two-year results from the Phase 3 MAESTRO-NAFLD-1 trial, ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price ...

Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...